Please assess the completion status of the following clinical trial:

Trial Title: Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy female postmenopausal volunteers, as defined by absence of menses for at least 12 months and follicle stimulating hormone (FSH) 30 IU/L;~2. Age 45 to 75 years;~3. Systolic blood pressure \<140 and \>90 mmHg and diastolic blood pressure \<90 and \>60 mmHg at the screening visit;~4. No personal history of diabetes;~5. Body mass index \< 30 kg/m2;~6. No clinically significant abnormalities on screening tests (complete blood count, serum electrolytes, liver enzymes, thyroid stimulating hormone, urinalysis, and electrocardiogram).~Exclusion Criteria:~1. Current smoking, defined as smoking within the 12 months before the screening visit;~2. Alcohol intake \>1 beverage per night or history of alcohol abuse;~3. Current or past recreational drug use;~4. Personal history of hypertension, cardiovascular disease (coronary artery disease, congestive heart failure, valvular heart disease, stroke, transient ischemic attack, or intermittent claudication), hyperlipidemia, diabetes (defined as a fasting glucose ≥126 mg/dL), kidney disease, liver disease, venous or arterial thromboembolic disease, adrenal insufficiency, depression, or illness requiring overnight hospitalization in the past 6 months;~5. Risk factors for arterial or venous thromboembolism;~6. Personal history of breast cancer or any other type of cancer;~7. Personal history of endometrial hyperplasia, endometrial cancer, or unexplained vaginal bleeding;~8. History of cervical cancer or abnormal pap smear~9. Prescription or herbal medication use, excluding thyroid hormone supplementation;~10. Ischemic changes on resting electrocardiogram;~11. Serum creatinine ≥ 1.3 mg/dL.~12. Serum potassium level \> 5.0 mmol/L;~13. Known hypersensitivity to any of the study drugs;~14. Other active medical problems detected by examination or laboratory testing, except for treated hypothyroidism.~15. Pregnancy

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Estradiol+MPA (Type: ACTIVE_COMPARATOR): None
- Estradiol+DRSP (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).